Artesunate (0.5–20 μM, 24 h) has been shown to substantially decrease VEGF, IL-8, p-Akt, and HIF-1α levels, collectively resulting in a 20–45% reduction in RA-FLS viability [18,19]. Here, AKT1 is linked to rheumatoid arthritis.